Neil Mahapatra, Managing Partner at Kingsley Capital Partners, is interviewed on developments in legal cannabis markets following the launch of Europe’s first ever cannabis-focused ETF Watch the full interview here.

For the past three decades, many of London’s five-star hotels—among them Claridge’s, the Connaught, the Berkeley, Rosewood, the Mandarin Oriental and Shangri-La—have turned to McQueens Flowers for the floral arrangements that subtly but unmistakably shift the weekly appearance of their lobbies, dining rooms and suites. McQueens’s creations have also been regular features at international events…

Medical cannabis brand Oxon is talking with investors about raising as much as $15m (£12m) as it prepares to launch a range of products in the UK and eyes a listing in London or the US. Oxon is part of Equinox International, whose main backer is private equity firm Kingsley Capital Partners. It wants to…

Whilst the wonders of cannabis have been touted for conditions such as cancer and arthritis, relatively little is known about the green leaf and its supposedly magical properties. That’s where Oxford Cannabinoid Technologies “OCT” comes in. The bio-tech start-up, founded by Kingsley Capital Partners, has been launched in partnership with the University of Oxford to…

Howard Marks made his name in the illicit drugs trade but the late drugs baron is making a posthumous comeback to cash in on a booming legal trade in cannabis-related products. Borrowing his most famous alias, the first Mr Nice store opened in London’s Soho district on Thursday, selling everything from upmarket bath bombs and…

Oxford Cannabinoid Technologies Ltd is working on breaking cannabis extractions down to their constituent parts then investigating potential uses in immunology, oncology, neurology and pain relief. The UK medical marijuana company backed by Snoop Dogg’s venture firm is targeting Big Pharma in its latest fundraising round and said drug makers getting involved in cannabis would…

[Neil] talks me through the business plan. Oxford Cannabinoid Technologies “OCT”, he explains, was set up to unravel the secrets of a plant that has been stigmatised for decades. Working with dozens of scientists at several universities it plans to isolate the active molecules in various strains of cannabis. These “cannabinoids” will be recombined to…

Managing Partner of Kingsley, Neil Mahapatra, was named as one of London’s most influential people for his work leading the charge for research into the potential medical benefits of cannabis. See here for the story.

Oxford university is to launch a £10m research programme in medical marijuana with venture capital funding, in the hope of developing treatments for pain, cancer and inflammatory disease. Kingsley Capital Partners, a private equity business based in London, has set up a company, Oxford Cannabinoid Technologies, to fund the research. Eight scientists at the university…